Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial
British Journal of Dermatology · 18.02.2025 · 192 (3) · 402-409
DOI: 10.1093/bjd/ljae406 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 22.10.2024. Verfasst von Jianzhong Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Psoriasis, Protein Kinase Inhibitors, Quinazolinones. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Background
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, is approved in the USA, the European Union, Japan, South Korea, China and other countries for the treatment of moderate-to-severe plaque psoriasis.
Objectives
To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate-to-severe plaque psoriasis.
Methods
In the 52-week blinded phase III POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Co-primary endpoints were the achievement of a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0/1) at week 16. Efficacy and safety were evaluated throughout.
Results
At week 16, significantly higher proportions of patients receiving deucravacitinib compared with placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.001). Response rates with deucravacitinib were maintained through week 52. Common adverse events (AEs) included upper respiratory tract infection and nasopharyngitis. Serious AE and discontinuation rates were low.
Conclusions
Deucravacitinib was efficacious and well tolerated in Asian patients with moderate-to-severe plaque psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Beijing, China.
- Shanghai Skin Disease Hospital, Shanghai, China.
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Beijing Friendship Hospital, Beijing, China.
- People's Hospital of Zhejiang Province, Hangzhou, China.
- Jiangsu Province Hospital, Nanjing, China.
ORCID-Profile: Yan Lu
Förderung
- Bristol Myers Squibb
Zitieren
APA
Zhang, J., Ding, Y., Wang, P., Li, L., Pan, W., Lu, Y., Cheng, H., Jiang, X., Ho, J. C., Guo, S., Liu, L., Chatterjee, A., Kisa, R. M., & Banerjee, S. (2025). Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial. British Journal of Dermatology, 192(3), 402-409. https://doi.org/10.1093/bjd/ljae406
Vancouver
Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, et al. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial. British Journal of Dermatology. 2025;192(3):402-409. doi:10.1093/bjd/ljae406
BibTeX
@article{Zhang2025,
author = {Zhang, Jianzhong and Ding, Yangfeng and Wang, Ping and Li, Linfeng and Pan, Weili and Lu, Yan and Cheng, Hao and Jiang, Xian and Ho, Ji-Chen and Guo, Shuping and Liu, Leona and Chatterjee, Arkendu and Kisa, Renata M and Banerjee, Subhashis},
title = {Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial},
journal = {British Journal of Dermatology},
year = {2025},
volume = {192},
number = {3},
pages = {402--409},
doi = {10.1093/bjd/ljae406}
}
EUVIMED